植入式与延长体外心电图监测对缺血性卒中患者心房颤动检出的影响:PER DIEM随机临床试验
PER DIEM随机临床试验在加拿大阿尔伯塔省2所大学医院和1所社区医院纳入300例6个月内缺血性卒中且无已知心房颤动的患者,1:1随机接受植入式循环记录仪(n=150)或体外循环记录仪(n=150)监测,随访12个月。主要终点为12个月内裁定新发心房颤动或高度可能心房颤动持续≥2分钟,植入式组15.3%(23/150)vs 体外组4.7%(7/150),组间差异10.7%(95%CI 4.0%至17.3%),风险比3.29(95%CI 1.45至7.42),P=0.003。8项预设次要终点中6项无显著差异,包括复发性缺血性卒中、脑出血、死亡和器械相关严重不良事件。作者结论认为植入式监测12个月可显著提高心房颤动检出比例,但需进一步研究比较临床结局和成本效益。
要点
- 缺血性卒中后无已知心房颤动患者,植入式循环记录仪监测12个月心房颤动检出率15.3%(23/150)vs 体外循环记录仪监测30天4.7%(7/150),风险比3.29(95%CI 1.45至7.42),P=0.003。
- 复发性缺血性卒中:植入式组3.3%(5/150)vs 体外组5.3%(8/150),组间差异-2.0%(95%CI -6.6%至2.6%),未达统计学显著。
- 脑出血:植入式组0.7%(1/150)vs 体外组0.7%(1/150),组间差异0%(95%CI -1.8%至1.8%);死亡:两组均2.0%(3/150),组间差异0%(95%CI -3.2%至3.2%)。
- 器械相关严重不良事件:植入式组0.7%(1/150)vs 体外组0%(0/150)。
- 8项预设次要终点中6项无显著差异;作者认为需进一步研究比较两种监测策略相关的临床结局和相对成本效益。
适用人群与场景
- 6个月内缺血性卒中且无已知心房颤动的患者,来自加拿大阿尔伯塔省2所大学医院和1所社区医院,随机化时间2015年5月至2017年11月,最终随访2018年12月。
- 纳入300例,中位年龄64.1岁(四分位距56.1至73.7岁),女性121例(40.3%),66.3%为不明病因卒中,中位CHA2DS2-VASc评分4分(四分位距3至5分)。
- 273例(91.0%)完成持续24小时或更长时间的心脏监测,259例(86.3%)完成指定监测和12个月随访。
诊断标准与关键阈值
- 主要终点为随机化后12个月内裁定新发心房颤动或高度可能心房颤动持续≥2分钟。
研究设计与关键结果
- 研究设计:研究者发起的开放标签随机临床试验,在2所大学医院和1所社区医院进行,300例患者1:1随机接受植入式循环记录仪(n=150)或体外循环记录仪(n=150)监测,随访访视在30天、6个月和12个月。
- 主要终点:植入式组15.3%(23/150)vs 体外组4.7%(7/150),组间差异10.7%(95%CI 4.0%至17.3%),风险比3.29(95%CI 1.45至7.42),P=0.003。
- 复发性缺血性卒中:植入式组3.3%(5/150)vs 体外组5.3%(8/150),组间差异-2.0%(95%CI -6.6%至2.6%)。
- 脑出血:植入式组0.7%(1/150)vs 体外组0.7%(1/150),组间差异0%(95%CI -1.8%至1.8%)。
- 死亡:植入式组2.0%(3/150)vs 体外组2.0%(3/150),组间差异0%(95%CI -3.2%至3.2%)。
- 器械相关严重不良事件:植入式组0.7%(1/150)vs 体外组0%(0/150)。
- 8项预设次要终点中6项无显著差异。
证据类型、等级与局限
- 证据类型:随机临床试验(开放标签)。
- 局限:作者结论指出需进一步研究比较这些监测策略相关的临床结局和相对成本效益。
对床旁实践的改变
- 对于6个月内缺血性卒中且无已知心房颤动的患者,与30天体外循环记录仪监测相比,12个月植入式循环记录仪监测可显著提高12个月内检出的心房颤动比例(15.3% vs 4.7%,风险比3.29,95%CI 1.45至7.42,P=0.003)。
- 作者认为需进一步研究比较两种监测策略相关的临床结局和相对成本效益。
指南或共识出处
- PER DIEM随机临床试验(NCT02428140),发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The relative rates of detection of atrial fibrillation (AF) or atrial flutter from evaluating patients with prolonged electrocardiographic monitoring with an external loop recorder or implantable loop recorder after an ischemic stroke are unknown.
OBJECTIVE: To determine, in patients with a recent ischemic stroke, whether 12 months of implantable loop recorder monitoring detects more occurrences of AF compared with conventional external loop recorder monitoring for 30 days.
DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, open-label, randomized clinical trial conducted at 2 university hospitals and 1 community hospital in Alberta, Canada, including 300 patients within 6 months of ischemic stroke and without known AF from May 2015 through November 2017; final follow-up was in December 2018.
INTERVENTIONS: Participants were randomly assigned 1:1 to prolonged electrocardiographic monitoring with either an implantable loop recorder (n = 150) or an external loop recorder (n = 150) with follow-up visits at 30 days, 6 months, and 12 months.
MAIN OUTCOMES AND MEASURES: The primary outcome was the development of definite AF or highly probable AF (adjudicated new AF lasting ≥2 minutes within 12 months of randomization). There were 8 prespecified secondary outcomes including time to event analysis of new AF, recurrent ischemic stroke, intracerebral hemorrhage, death, and device-related serious adverse events within 12 months.
RESULTS: Among the 300 patients who were randomized (median age, 64.1 years [interquartile range, 56.1 to 73.7 years]; 121 were women [40.3%]; and 66.3% had a stroke of undetermined etiology with a median CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years, diabetes, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category] score of 4 [interquartile range, 3 to 5]), 273 (91.0%) completed cardiac monitoring lasting 24 hours or longer and 259 (86.3%) completed both the assigned monitoring and 12-month follow-up visit. The primary outcome was observed in 15.3% (23/150) of patients in the implantable loop recorder group and 4.7% (7/150) of patients in the external loop recorder group (between-group difference, 10.7% [95% CI, 4.0% to 17.3%]; risk ratio, 3.29 [95% CI, 1.45 to 7.42]; P = .003). Of the 8 specified secondary outcomes, 6 were not significantly different. There were 5 patients (3.3%) in the implantable loop recorder group who had recurrent ischemic stroke vs 8 patients (5.3%) in the external loop recorder group (between-group difference, -2.0% [95% CI, -6.6% to 2.6%]), 1 (0.7%) vs 1 (0.7%), respectively, who had intracerebral hemorrhage (between-group difference, 0% [95% CI, -1.8% to 1.8%]), 3 (2.0%) vs 3 (2.0%) who died (between-group difference, 0% [95% CI, -3.2% to 3.2%]), and 1 (0.7%) vs 0 (0%) who had device-related serious adverse events.
CONCLUSIONS AND RELEVANCE: Among patients with ischemic stroke and no prior evidence of AF, implantable electrocardiographic monitoring for 12 months, compared with prolonged external monitoring for 30 days, resulted in a significantly greater proportion of patients with AF detected over 12 months. Further research is needed to compare clinical outcomes associated with these monitoring strategies and relative cost-effectiveness.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02428140.
参考来源
- Buck BH, Hill MD, Quinn FR, et al. Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial. JAMA. 2021. PMID: 34061146. doi:10.1001/jama.2021.6128
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。